Family and Friends Homecare Elevates In-Home Care, Impacting Lives Across Lakewood, CO
Lakewood, CO - Family and Friends Homecare today announced its ongoing commitment to enhancing the lives of local seniors through its exceptional in-home caregiver services. The agency continues to set the benchmark for quality, compassionate care, ensuring that every family in Lakewood, CO, has access to the very best support for their elderly loved ones right in the comfort of their own homes.
As the demand for personalized senior care grows, Family and Friends Homecare is dedicated to a model that prioritizes dignity, independence, and well-being. By allowing seniors to age in place, the agency helps maintain their connection to familiar surroundings and cherished routines. As an expert in home caregiver in Lakewood, CO, the company provides tailored, one-on-one attention that is simply not possible in larger facility settings, fostering a greater sense of security and personal freedom for clients.
The benefits of this dedicated approach extend beyond basic assistance. A professional caregiver for elderly in Lakewood from Family and Friends Homecare offers crucial companionship that combats loneliness and promotes mental and emotional health. This holistic support system also provides families with invaluable peace of mind, knowing their loved one is in the hands of a trusted, skilled, and compassionate professional. Services are customized to each client's unique needs, from meal preparation and light housekeeping to medication reminders and personal care.
"Our mission has always been to treat every client like a member of our own family," said Jon Cohen, founder of Family and Friends Homecare. "We believe that providing a dedicated caregiver is about more than just assistance; it's about building trusting relationships and ensuring our seniors can live with dignity, comfort, and joy in the place they love most. We are deeply committed to being the best for our community here in Lakewood."
Founded on the principle that home is the best place to be, Family and Friends Homecare implements a rigorous screening and training process for all its caregivers. This ensures that every team member not only possesses the necessary skills but also shares the company's core values of empathy, respect, and integrity. The agency's deep roots in the Lakewood community drive its focus on creating perfect matches between clients and caregivers, leading to lasting and meaningful relationships.
Families in Lakewood and surrounding areas who are seeking reliable, high-quality in-home care for their elderly loved ones are encouraged to learn more about the services offered by Family and Friends Homecare. The agency provides flexible care plans tailored to fit the specific needs and schedules of each family.
For more information about Family and Friends Homecare and their in-home caregivers in Lakewood, CO, please visit their website at https://fafhc.com
About Family and Friends Homecare:
Family and Friends Homecare is a premier provider of non-medical, in-home care services for seniors in Lakewood, CO, and the surrounding communities. With a focus on compassionate, client-centered care, the agency enables seniors to live independently and with dignity in their own homes.
Media Contact
Company Name: Family and Friends Homecare
Email: Send Email
Phone: (720) 759-3762
Address: 245 S BENTON ST
City: LAKEWOOD
State: Colorado
Country: United States
Website: https://fafhc.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Trump pressures 17 pharma CEOs to cut U.S. drug prices
Pills spill in an arrangement photo of prescription Oxycodone in New York. (AP Photo/Mark Lennihan, File) U.S. President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about two per cent each, while the NYSE Arca Pharmaceutical Index fell three per cent on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until Sept. 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said. Jeff Mason, Nandita Bose, Patrick Wingrove, Reuters
CBC
2 hours ago
- CBC
Trump administration to burn $13M worth of female contraceptives, despite NGO's offer to take them
The U.S. State Department plans to incinerate roughly $13.2 million worth of women's contraceptives despite offers from multiple aid agencies to distribute the supplies at no cost. The supplies, which include various forms of birth control, were intended for family planning programs in low-income African nations. Instead, they've been sitting in a warehouse in Belgium for months after President Donald Trump's administration froze most foreign aid in January. MSI Reproductive Choices, a U.K.-based global reproductive health organization, says it offered to take the supplies and distribute them to those in need at no cost to the government, but their offer was rebuked. "To me that sends a really clear signal that this is an ideological position," Sarah Shaw, MSI's director of advocacy, told As It Happens guest host Paul Hunter. "This is just another front on the war on women that we're currently seeing coming out of the U.S., both domestically and internationally." Shaw says MSI was told through an intermediary that the government wants to sell the products at market value, which the charity could not afford to do. The United Nations' sexual and reproductive health agency, UNFPA, offered to buy the contraceptives outright, also to no avail, according to Reuters. The U.S. State Department did not respond to questions from CBC. But spokesperson Tommy Pigott told reporters on Thursday the government is "still in the process of determining the pathway forward." Belgium calls it a 'regrettable outcome' The supplies, valued at $9.7 million US, once belonged to the United States Agency for International Development (USAID), which the Trump administration has shut down. During a press briefing on Thursday, Pigott said the supplies do not include condoms or HIV medication, but rather "select products" purchased under the previous administration that "could potentially be abortifacients," meaning products that induce abortion. But aid agencies and media organizations say the supplies slated for destruction are designed to prevent unwanted pregnancies, not terminate them. Reuters, citing seven confidential sources close to the story, reports the warehouse contains contraceptive pills and implants, as well as intrauterine devices, all of which are forms of birth control. Pigott said the products could be in contravention of the Kemp-Kasten amendment, which prevents the government from supporting programs that engage in "coercive abortion or involuntary sterilization," as well as the Mexico City policy, a pact that prohibits the U.S. government from contributing to or working with organizations that provide abortion-related services or information. The latter could explain why the U.S. declined MSI's offer, says Shaw. Her organization refuses to comply with the Mexico City policy, which she and other aid organizations refer to as "the global gag order." But it doesn't explain why they've rejected similar overtures from others trying to prevent the contraceptives from going to waste at taxpayer expense, she said. The Belgian foreign ministry said Brussels had held talks with U.S. authorities and "explored all possible options to prevent the destruction, including temporary relocation." "Despite these efforts, and with full respect for our partners, no viable alternative could be secured. Nevertheless, Belgium continues to actively seek solutions to avoid this regrettable outcome," it said in a statement. "Sexual and reproductive health must not be subject to ideological constraints." Uproar in France The State Department previously confirmed it will spend $167,000 US ($228,000 Cdn) to incinerate the contraceptives at a facility in France that handles medical waste. That news is not sitting well in France, where lawmakers, reproductive health organizations and feminist groups are calling on the government to call it off. "We are following this situation closely and we support the will of the Belgian authorities to find a solution to avoid the destruction of contraceptives," France's foreign ministry said in a statement published by the Guardian. "The defence of sexual health and reproductive rights is a foreign policy priority for France." WATCH | Global health funding in a state of crisis: U.S. foreign aid cuts fuelling 'era of global health austerity': study 15 days ago After the White House's push to dismantle the United States Agency for International Development (USAID) cancelled billions of dollars in spending for foreign aid, researchers say global health funding is expected to reach a 15-year low. Read more: Shaw says she's grateful to the people in France who are championing this cause. "Even if we can't stop the destruction we're not going to let this go quietly," she said. "If this happens on French soil under a government that has a feminist foreign policy, I think that would be a great shame, a great shame." Doctors Without Borders calls plan 'reckless and harmful' Avril Benoît, the CEO of Doctors Without Borders in the U.S., called the plan a "reckless and harmful act against women and girls everywhere." "Contraceptives are essential and lifesaving health products," she said in a press release. "[Our organization] has seen first-hand the positive health benefits when women and girls can freely make their own health decisions by choosing to prevent or delay pregnancy — and the dangerous consequences when they cannot." Shaw agrees. She says the U.S. has made a big deal about finding government efficiencies as it slashes global aid and its own civil service. But every dollar spent on reproductive health, she says, leads to much greater savings down the road. "It makes no sense to me. If they really want efficiency, investing in family planning is the best investment you can make for development," she said. "You keep girls in schools. You break generational cycles of poverty. You create opportunity for a new generation of young women.
National Post
4 hours ago
- National Post
MindMed Reports Q2 2025 Financial Results and Business Updates
Article content –Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)– Article content –Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD anticipated in 2H 2026– Article content Article content –Strengthened leadership team with appointment of Brandi L. Roberts as Chief Financial Officer– Article content –Conference call scheduled today at 4:30 p.m. EDT– Article content NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights. 'We continue making significant progress across all three of our pivotal Phase 3 trials evaluating MM120 ODT in GAD and MDD, with ongoing enthusiasm from both trial sites and participants driving strong enrollment,' said Rob Barrow, Chief Executive Officer of MindMed. 'We remain on track to report topline data from our Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half of the year. In parallel, we are advancing our commercial strategy and have continued to strengthen our leadership team with the appointment of Brandi Roberts as Chief Financial Officer. With our clearly defined regulatory strategy, disciplined operational execution, and strong balance sheet, we are well-positioned to advance MM120 ODT as a potential best-in-class therapeutic option for the treatment of GAD and MDD.' Article content Business Highlights Article content Progressing Pivotal Trials: Strong enrollment continues across all three MM120 ODT Phase 3 trials: Voyage and Panorama in GAD and Emerge in MDD. The continued execution reinforces the Company's targeted trial timelines and progress in preparing for a potential NDA filing. Strengthened Leadership for Growth: Appointed Brandi L. Roberts as Chief Financial Officer. Ms. Roberts brings more than 25 years of financial leadership experience within the life sciences industry. As a member of the executive team, she leads all aspects of the Company's financial strategy, capital planning, accounting, investor relations and information technology. Article content MM120 ODT (lysergide D-tartrate) for GAD Article content Enrollment is on track in the Phase 3 Voyage study of MM120 ODT for the treatment of GAD. Voyage is expected to enroll approximately 200 participants in the U.S. who will be randomized 1:1 to receive MM120 ODT 100 µg or placebo. Topline data from the 12-week double-blind period (Part A) is anticipated in the first half of 2026. Enrollment is on track in the Panorama study, the Company's second Phase 3 study of MM120 ODT for the treatment of GAD. Panorama is expected to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 µg, MM120 ODT 50 µg or placebo) in the U.S. and Europe. Topline data from the 12-week double-blind period (Part A) is anticipated in the second half of 2026. Article content MM120 (lysergide D-tartrate) for MDD Article content Enrollment is on track in the Phase 3 Emerge study of M120 ODT for the treatment of MDD. Emerge is expected to enroll 140 participants (randomized 1:1 to receive MM120 ODT 100 µg or placebo). Topline data from the 12-week double-blinded period (Part A) is anticipated in the second half of 2026. The Company expects to conduct a second Phase 3 registrational study in MDD, with the study design and timing to be informed by the progress of Emerge and additional regulatory discussions. Article content MM402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD) Article content Completed a Phase 1 study of MM402, a single-ascending dose study in adult healthy volunteers. The study characterized the tolerability, pharmacokinetics and pharmacodynamics of MM402. The Company expects to initiate further studies of MM402 to assess its potential efficacy for the treatment of ASD. Article content Cash Balance. Article content As of June 30, 2025, MindMed had cash, cash equivalents and investments totaling $237.9 million compared to $245.5 million as of March 31, 2025. Article content Based on the Company's current operating plan and anticipated R&D milestones, the Company believes that its cash, cash equivalents and investments as of June 30, 2025 will be sufficient to fund the Company's operations into 2027 and at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD. Article content Research and Development (R&D). Article content R&D expenses were $29.8 million for the quarter ended June 30, 2025, compared to $14.6 million for the quarter ended June 30, 2024, an increase of $15.2 million. The net increase of $15.2 million was primarily related to increases of $14.5 million related to our MM120 ODT program, $1.5 million in internal personnel costs as a result of increased headcount, and $0.2 million related to preclinical activities, offset by a decrease of $1.0 million in MM402 program expenses based on the timing of studies. Article content General and Administrative (G&A). Article content G&A expenses were $11.1 million for the quarter ended June 30, 2025, compared to $9.8 million for the quarter ended June 30, 2024, an increase of $1.3 million. The increase was primarily related to increases in personnel costs as a result of increased headcount. Article content Net Loss. Article content Net loss for the quarter ended June 30, 2025, was $42.7 million, compared to $5.9 million for the same period in 2024, a decrease of $36.8 million. The decrease was primarily due to increases in operating expenses of $16.4 million, changes in the fair value of warrants issued in our September 2022 underwritten offering of $15.6 million, the absence of a $2.5 million gain on extinguishment of contribution payable from 2024 and increased interest expense related primarily to the amendment of our credit facility of $1.8 million. Article content Conference Call and Webcast Reminder Article content MindMed management will host a webcast at 4:30 p.m. EDT today to provide a corporate update and review the Company's second quarter 2025 financial results, and business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. Article content About MM120 Orally Disintegrating Tablet (ODT) Article content MM120 ODT (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics which acts as a partial agonist at human serotonin-2A (5-HT2A) receptors. MM120 ODT is MindMed's proprietary and pharmaceutically optimized form of LSD. MM120 ODT is an advanced formulation incorporating Catalent's Zydis® ODT fast-dissolve technology which has a unique clinical profile with more rapid absorption, improved bioavailability and reduced gastrointestinal side effects. MindMed is developing MM120, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and is exploring its potential applications in other serious brain health disorders. Article content About MM402 Article content MM402 is the Company's proprietary form of R(-)-MDMA (rectus-3,4-methylenedioxymethamphetamine), being developed for the treatment of core symptoms of Autism Spectrum Disorder (ASD). MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrate its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggest that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer. Article content About MindMed Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD. Article content Forward-Looking Statements Article content Certain statements in this news release related to the Company constitute 'forward-looking information' within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'will', 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe', 'potential' or 'continue', or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company's anticipated topline readout (Part A results) for the Phase 3 Voyage study of MM120 ODT in GAD in the first half of 2026; the Company's anticipated topline readout (Part A results) for the Phase 3 Panorama study for MM120 ODT in GAD in the second half of 2026; the Company's anticipated topline readout (Part A results) for the Phase 3 Emerge study for MM120 ODT in MDD in the second half of 2026; the Company's plans to conduct a second Phase 3 study in MDD; the Company's expectations regarding the enrollment for each of the Voyage, Panorama and Emerge studies; the Company's beliefs regarding potential benefits of its product candidates; the Company's expectation to conduct further studies of MM402; the Company's expectation that its cash, cash equivalents and investments will fund operations into 2027; the Company's expectation that its cash runway will extend at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD; and potential additional indications for MM120 ODT and MM402. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection; as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 under headings such as 'Special Note Regarding Forward-Looking Statements,' and 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise. Article content Mind Medicine (MindMed) Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2025 2024 2025 2024 Operating expenses: Research and development $ 29,809 $ 14,645 $ 53,166 $ 26,350 General and administrative 11,094 9,813 19,896 20,312 Total operating expenses 40,903 24,458 73,062 46,662 Loss from operations (40,903 ) (24,458 ) (73,062 ) (46,662 ) Other income/(expense): Interest income 2,774 3,116 5,207 4,772 Interest expense (2,338 ) (466 ) (2,940 ) (900 ) Foreign exchange loss, net (49 ) (32 ) (68 ) (557 ) Change in fair value of 2022 USD Financing Warrants (2,228 ) 13,445 4,771 (19,448 ) Gain on extinguishment of contribution payable — 2,541 — 2,541 Total other income/(expense) (1,841 ) 18,604 6,970 (13,592 ) Net loss (42,744 ) (5,854 ) (66,092 ) (60,254 ) Other comprehensive loss Unrealized gain on investments 36 — 46 — Gain/(loss) on foreign currency translation (31 ) (3 ) (58 ) 490 Comprehensive loss $ (42,739 ) $ (5,857 ) $ (66,104 ) $ (59,764 ) Net loss per common share, basic $ (0.50 ) $ (0.08 ) $ (0.78 ) $ (1.01 ) Net loss per common share, diluted $ (0.50 ) $ (0.26 ) $ (0.81 ) $ (1.01 ) Article content Article content Article content Article content Article content Contacts Article content For Media: Article content Article content Article content
